Literature DB >> 29663062

[Follow-up of bladder cancer : The right examinations at the right time].

P Olbert1, P J Goebell2, A Hegele3.   

Abstract

Schedules for the follow-up (FU) of bladder cancer patients are predominantly based on studies with low level of evidence and the resulting guidelines' recommendations that are often founded on expert consensus. FU of non-muscle invasive bladder cancer (NMIBC) includes cystoscopy and cytology as standard, and imaging modalities to a lower extent. FU of muscle-invasive bladder cancer (MIBC) depends primarily on the therapeutic modality chosen and on the stage of disease. In this scenario, FU is complemented by functional and quality of life related aspects. These apply even more for FU in palliative situations. Here, the individual focus is on examinations that might have a consequence in terms of survival and/or symptom relief.

Entities:  

Keywords:  Chemoradiotherapy; Cystectomy; Cystoscopy; Urinary bladder; Urothelial carcinoma

Mesh:

Year:  2018        PMID: 29663062     DOI: 10.1007/s00120-018-0641-3

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  59 in total

Review 1.  Staged based directed surveillance of invasive bladder cancer following radical cystectomy: valuable and effective?

Authors:  S Machele Donat
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

Review 2.  Metabolic consequences of continent urinary diversion.

Authors:  R D Mills; U E Studer
Journal:  J Urol       Date:  1999-04       Impact factor: 7.450

3.  Urethral recurrence in patients with orthotopic ileal neobladders.

Authors:  J A Freeman; T A Tarter; D Esrig; J P Stein; D A Elmajian; S C Chen; S Groshen; G Lieskovsky; D G Skinner
Journal:  J Urol       Date:  1996-11       Impact factor: 7.450

4.  Urethral recurrence after cystoprostatectomy: implications for urinary diversion and monitoring.

Authors:  Alan M Nieder; Paul D Sved; Pablo Gomez; Sandy S Kim; Murugesan Manoharan; Mark S Soloway
Journal:  Urology       Date:  2004-11       Impact factor: 2.649

5.  Risk factors for upper tract recurrence in patients undergoing long-term surveillance for stage ta bladder cancer.

Authors:  Benjamin K Canales; James K Anderson; Juan Premoli; Joel W Slaton
Journal:  J Urol       Date:  2006-01       Impact factor: 7.450

6.  Clinical experience with radiotherapy alone and radiochemotherapy with platin based regimens in organ-sparing treatment of invasive bladder cancer.

Authors:  Hanan Sh Gamal El-Deen; Hala F Elshazly; Esam A Abo Zeina
Journal:  J Egypt Natl Canc Inst       Date:  2009-03

Review 7.  Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy.

Authors:  Georgios Gakis; Peter C Black; Bernard H Bochner; Stephen A Boorjian; Arnulf Stenzl; George N Thalmann; Wassim Kassouf
Journal:  Eur Urol       Date:  2016-10-06       Impact factor: 20.096

Review 8.  Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer.

Authors:  Bernard H Bochner; James E Montie; Cheryl T Lee
Journal:  Urol Clin North Am       Date:  2003-11       Impact factor: 2.241

9.  The risk factor for urethral recurrence after radical cystectomy in patients with transitional cell carcinoma of the bladder.

Authors:  Kang Su Cho; Joo Wan Seo; Sung Jin Park; Young Hoon Lee; Young Deuk Choi; Nam Hoon Cho; Seung Choul Yang; Sung Joon Hong
Journal:  Urol Int       Date:  2009-05-11       Impact factor: 2.089

Review 10.  Management of muscle-invasive bladder cancer: an update.

Authors:  Mohamed A Ghoneim; Hassan Abol-Enein
Journal:  Nat Clin Pract Urol       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.